Moving forward, priorities include: (i) in vivo pharmacokinetics and pharmacodynamics to address the size–stability relationship (e.g., DLS ≈133 nm vs. FE‐SEM ≈125 nm) via surface engineering such as PEGylation to extend circulation half‐life; (ii) anti‐inflammatory validation in relevant tumor models with IL‐6/COX‐2 endpoints; (iii) eco‐toxicology profiling using Daphnia magna to establish environmental safety; and (iv) formulation development, including lyophilized VACAgNPs with trehalose for intravenous delivery (Huang et al. 2018). The gene discussed is IL6; the disease is neoplasm.